novavax: Serum Institute gets USFDA nod to export Novavax covid jab to US

The USFDA approval makes SII – the primary Indian vaccine maker to export vaccines to the US market, an affidavit to the corporate’s talents to provide vaccines underneath stringent high quality expectations.

“It in an necessary milestone for the vaccine trade this week as #Nuvaxovid (@Novavax) made by @SerumInstIndia in India is permitted by the @US_FDA and is being exported to america of America for the primary time,” SII stated in a tweet on Friday.

SII is a key companion for Novovax, which has signed as much as manufacture Nuvaxovid from its facility in Pune. Nuvaxovid is already being exported to extremely regulated markets reminiscent of Europe, Australia and different nations.

The Maryland-based biotech has acquired approval from USFDA for its Covid jab on Wednesday for adults. The vaccine is a protein sub-unit and thought of to be a secure possibility based mostly on a tried and examined platform. Novavax approval within the US is for 2 doses, nevertheless the corporate is positioning the vaccine as a booster shot to different Covid vaccines.

The US authorities has purchased 3.2 million doses of Novavax vaccine which is predicted to be rolled out by the tip of this month.

SII can be on the point of work with Novavax on an Omicron variant-specific vaccine for Covid-19 that might be completely different from the unique shot developed utilizing the Wuhan pressure of the Sars-CoV-2 virus.